{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:17:07Z","timestamp":1788545827194,"version":"build-2803163510"},"reference-count":128,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.neurol.2023.03.006","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T11:59:05Z","timestamp":1679399945000},"page":"449-463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Innovative treatments for meningiomas"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5627-8181","authenticated-orcid":false,"given":"T.","family":"Graillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tabouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0889-0226","authenticated-orcid":false,"given":"B.","family":"Salgues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-309X","authenticated-orcid":false,"given":"T.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4545-6063","authenticated-orcid":false,"given":"R.","family":"Appay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-0016","authenticated-orcid":false,"given":"K.","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"R\u00e9gis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Barlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Chinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.neurol.2023.03.006_bib0645","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0650","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neuchi.2014.11.013","article-title":"Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006\u20132010","volume":"64","author":"Zouaoui","year":"2018","journal-title":"Neurochirurgie"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0655","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1186\/s12885-018-4545-9","article-title":"Increasing incidence of central nervous system (CNS) tumors (2000\u20132012): findings from a population based registry in Gironde (France)","volume":"18","author":"Pouchieu","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0660","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neuchi.2014.05.006","article-title":"Epidemiology of meningiomas","volume":"64","author":"Baldi","year":"2018","journal-title":"Neurochirurgie"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0665","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11060-022-04085-6","article-title":"Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018","volume":"160","author":"Recker","year":"2022","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0670","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1227\/NEU.0b013e31822d408a","article-title":"Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients","volume":"70","author":"Santacroce","year":"2012","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib0675","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0360-3016(02)04356-0","article-title":"Stereotactic radiosurgery provides equivalent tumor control to Simpson Grade 1 resection for patients with small- to medium-size meningiomas","volume":"55","author":"Pollock","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.006_bib0680","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/neuros\/nyy009","article-title":"Stereotactic Radiosurgery for Benign (World Health Organization Grade I) Cavernous Sinus Meningiomas-International Stereotactic Radiosurgery Society (ISRS) Practice Guideline: a systematic review","volume":"83","author":"Lee","year":"2018","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0685","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00701-021-05056-y","article-title":"Stereotactic radiosurgery for asymptomatic petroclival region meningiomas: a focused analysis from the IMPASSE study","volume":"164","author":"Mantziaris","year":"2022","journal-title":"Acta Neurochir (Wien)"},{"issue":"16","key":"10.1016\/j.neurol.2023.03.006_bib0690","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.3390\/cancers14164047","article-title":"Stereotactic radiosurgery for benign cavernous sinus meningiomas: a multicentre study and review of the literature","volume":"14","author":"Santacroce","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neurol.2023.03.006_bib0695","doi-asserted-by":"crossref","first-page":"100864","DOI":"10.1016\/j.bas.2022.100864","article-title":"Management of cavernous sinus meningiomas: consensus statement on behalf of the EANS skull base section","volume":"2","author":"Corniola","year":"2022","journal-title":"Brain Spine"},{"issue":"8","key":"10.1016\/j.neurol.2023.03.006_bib0700","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib0705","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bpa.12524","article-title":"Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis","volume":"28","author":"Tauziede-Espariat","year":"2018","journal-title":"Brain Pathol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0710","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00401-020-02161-7","article-title":"Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features","volume":"140","author":"Williams","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib0715","first-page":"535","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0720","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/jnen\/nlv006","article-title":"Meningiomas with rhabdoid features lacking other histologic features of malignancy: a study of 44 cases and review of the literature","volume":"75","author":"Vaubel","year":"2016","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib0725","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib0730","doi-asserted-by":"crossref","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.neurol.2023.03.006_bib0735","article-title":"Genomic landscape of high-grade meningiomas","volume":"2:15","author":"Bi","year":"2017","journal-title":"NPJ Genom Med"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib0740","first-page":"345","article-title":"SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas","volume":"19","author":"Boetto","year":"2017","journal-title":"Neuro Oncol"},{"issue":"6123","key":"10.1016\/j.neurol.2023.03.006_bib0745","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.neurol.2023.03.006_bib0750","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ng.3651","article-title":"Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas","volume":"48","author":"Clark","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurol.2023.03.006_bib0755","article-title":"Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade","volume":"2018:PO.18.00190","author":"Dunn","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib0760","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.006_bib0765","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","article-title":"DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib0770","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib0775","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","article-title":"mTORC1 inhibitors suppress meningioma growth in mouse models","volume":"19","author":"Pachow","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib0780","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3171\/2009.7.JNS09726","article-title":"Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway","volume":"112","author":"Johnson","year":"2010","journal-title":"J Neurosurg"},{"issue":"15","key":"10.1016\/j.neurol.2023.03.006_bib0785","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0790","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-015-1812-3","article-title":"Combined treatment by octreotide and everolimus: octreotide enhances inhibitory effect of everolimus in aggressive meningiomas","volume":"124","author":"Graillon","year":"2015","journal-title":"J Neurooncol"},{"issue":"33","key":"10.1016\/j.neurol.2023.03.006_bib0795","doi-asserted-by":"crossref","first-page":"55361","DOI":"10.18632\/oncotarget.19517","article-title":"Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro","volume":"8","author":"Graillon","year":"2017","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.neurol.2023.03.006_bib0800","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.3390\/cancers14184448","article-title":"Co-targeting MAP kinase and Pi3K-Akt-mTOR pathways in meningioma: preclinical study of alpelisib and trametinib","volume":"14","author":"Mondielli","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.neurol.2023.03.006_bib0805","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1007\/s13277-015-3388-0","article-title":"A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt\/beta-catenin signaling pathway","volume":"36","author":"Das","year":"2015","journal-title":"Tumour Biol"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib0810","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11060-008-9746-7","article-title":"Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas","volume":"92","author":"Johnson","year":"2009","journal-title":"J Neurooncol"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.006_bib0815","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/1078-0432.CCR-04-2550","article-title":"Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas","volume":"11","author":"Mawrin","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0820","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12672-021-00449-y","article-title":"Focal adhesion kinase inhibitors, a heavy punch to cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Discov Oncol"},{"issue":"237","key":"10.1016\/j.neurol.2023.03.006_bib0825","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib0830","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","article-title":"The Hippo pathway and human cancer","volume":"13","author":"Harvey","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"Supplement_2","key":"10.1016\/j.neurol.2023.03.006_bib0835","doi-asserted-by":"crossref","first-page":"ii95","DOI":"10.1093\/neuonc\/noac174.334","article-title":"P18.07.A Hippo signaling pathway is strongly involved in meningioma tumorigenesis","volume":"24","author":"Mougel","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.006_bib0840","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/1541-7786.MCR-12-0116","article-title":"Yes-associated protein 1 is activated and functions as an oncogene in meningiomas","volume":"10","author":"Baia","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.006_bib0845","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1593\/neo.08642","article-title":"The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP","volume":"10","author":"Striedinger","year":"2008","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.006_bib0850","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","article-title":"Small molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma","volume":"20","author":"Tang","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib0855","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3171\/2016.8.JNS16995","article-title":"Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review","volume":"127","author":"Graillon","year":"2017","journal-title":"J Neurosurg"},{"issue":"10","key":"10.1016\/j.neurol.2023.03.006_bib0860","first-page":"13185","article-title":"Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance","volume":"8","author":"Silva","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib0865","first-page":"485","article-title":"Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density?","volume":"20","author":"Barresi","year":"2008","journal-title":"Oncol Rep"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib0870","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5414\/NPP27334","article-title":"Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes","volume":"27","author":"Durand","year":"2008","journal-title":"Clin Neuropathol"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib0875","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S","article-title":"Expression of somatostatin receptor subtypes in human brain tumors","volume":"76","author":"Dutour","year":"1998","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib0880","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s10143-022-01849-6","article-title":"Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data","volume":"45","author":"Jensen","year":"2022","journal-title":"Neurosurg Rev"},{"issue":"12","key":"10.1016\/j.neurol.2023.03.006_bib0885","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","article-title":"PET imaging in patients with meningioma-report of the RANO\/PET Group","volume":"19","author":"Galldiks","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib0890","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","article-title":"Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma","volume":"84","author":"Norden","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib0895","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1590\/1414-431x20144163","article-title":"Abundant immunohistochemical expression of dopamine D2 receptor and p53 protein in meningiomas: follow-up, relation to gender, age, tumor grade, and recurrence","volume":"48","author":"Trott","year":"2015","journal-title":"Braz J Med Biol Res"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.006_bib0900","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1210\/jcem-71-6-1669","article-title":"Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors","volume":"71","author":"Schrell","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib0905","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00006123-199602000-00027","article-title":"Dopamine D1, dopamine D2, and prolactin receptor messenger ribonucleic acid expression by the polymerase chain reaction in human meningiomas","volume":"38","author":"Carroll","year":"1996","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib0910","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3171\/jns.1992.77.2.0288","article-title":"Presence of dopamine D1 receptors and absence of dopamine D2 receptors in human cerebral meningioma tissue","volume":"77","author":"Schrell","year":"1992","journal-title":"J Neurosurg"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib0915","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3171\/jns.1990.73.5.0750","article-title":"Hormonal dependency of cerebral meningiomas. Part 2: In vitro effect of steroids, bromocriptine, and epidermal growth factor on growth of meningiomas","volume":"73","author":"Adams","year":"1990","journal-title":"J Neurosurg"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib0920","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/09513590.2010.487620","article-title":"Further data favouring hormonal dependency of cerebral meningiomas: evidence from a patient treated with cabergoline","volume":"27","author":"Castelo-Branco","year":"2011","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0925","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13073-022-01051-9","article-title":"Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune response","volume":"14","author":"Wang","year":"2022","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib0930","doi-asserted-by":"crossref","first-page":"e1512943","DOI":"10.1080\/2162402X.2018.1512943","article-title":"Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma","volume":"8","author":"Proctor","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.neurol.2023.03.006_bib0935","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3389\/fonc.2019.01109","article-title":"Possible abscopal effect observed in frontal meningioma after localized IMRT on posterior meningioma resection cavity without adjuvant immunotherapy","volume":"9","author":"Golub","year":"2019","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib0940","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11060-016-2256-0","article-title":"Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma","volume":"130","author":"Han","year":"2016","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib0945","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-020-03584-8","article-title":"Clinical significance of checkpoint regulator \u201cProgrammed death ligand-1 (PD-L1)\u201d expression in meningioma: review of the current status","volume":"151","author":"Karimi","year":"2021","journal-title":"J Neurooncol"},{"issue":"9","key":"10.1016\/j.neurol.2023.03.006_bib0950","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/ene.15423","article-title":"Risk of intracranial meningioma with three potent progestogens: a population-based case-control study","volume":"29","author":"Hoisnard","year":"2022","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.006_bib0955","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.neuchi.2021.04.018","article-title":"Meningiomas in patients with long-term exposition to progestins: characteristics and outcome","volume":"67","author":"Graillon","year":"2021","journal-title":"Neurochirurgie"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib0960","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/annonc\/mdx763","article-title":"Progestin-associated shift of meningioma mutational landscape","volume":"29","author":"Peyre","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.006_bib0965","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"Chamberlain","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib0970","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J Neurooncol"},{"issue":"15_suppl.","key":"10.1016\/j.neurol.2023.03.006_bib0975","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.2019.37.15_suppl.2007","article-title":"Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)","volume":"37","author":"Preusser","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib0980","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J Neurooncol"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib0985","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","article-title":"Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma","volume":"107","author":"Chamberlain","year":"2012","journal-title":"J Neurooncol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib0990","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0028-3770(04)98326-9","article-title":"[Hydroxyurea treatment for unresectable meningioma]","volume":"50","author":"Fuentes","year":"2004","journal-title":"Neurochirurgie"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib0995","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11060-004-2337-3","article-title":"Prolonged oral hydroxyurea and concurrent 3D-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study","volume":"74","author":"Hahn","year":"2005","journal-title":"J Neurooncol"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.006_bib1000","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3340\/jkns.2012.52.6.517","article-title":"Long-term follow-up result of hydroxyurea chemotherapy for recurrent meningiomas","volume":"52","author":"Kim","year":"2012","journal-title":"J Korean Neurosurg Soc"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib1005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3171\/jns.2002.97.2.0341","article-title":"Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma","volume":"97","author":"Mason","year":"2002","journal-title":"J Neurosurg"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib1010","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/FOC-07\/10\/E11","article-title":"Hydroxyurea chemotherapy in the treatment of meningiomas","volume":"23","author":"Newton","year":"2007","journal-title":"Neurosurg Focus"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib1015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3171\/jns.1997.86.5.0845","article-title":"Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway","volume":"86","author":"Schrell","year":"1997","journal-title":"J Neurosurg"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.006_bib1020","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/WCO.0000000000001002","article-title":"Chemotherapy and targeted therapies for meningiomas: what is the evidence?","volume":"34","author":"Graillon","year":"2021","journal-title":"Curr Opin Neurol"},{"issue":"34","key":"10.1016\/j.neurol.2023.03.006_bib1025","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2015.61.6490","article-title":"Double-blind Phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005","volume":"33","author":"Ji","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.006_bib1030","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib1035","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3171\/2018.6.JNS181418","article-title":"Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma","volume":"129","author":"Jenkinson","year":"2018","journal-title":"J Neurosurg"},{"key":"10.1016\/j.neurol.2023.03.006_bib1040","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/s13063-015-1040-3","article-title":"The ROAM\/EORTC-1308 trial: radiation versus observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial","volume":"16","author":"Jenkinson","year":"2015","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/neuros\/nyaa333","article-title":"Simpson Grade Revisited - Intraoperative estimation of the extent of resection in meningiomas versus postoperative somatostatin receptor positron emission tomography\/computed tomography and magnetic resonance imaging","volume":"88","author":"Ueberschaer","year":"2020","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1050","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00259-020-04894-9","article-title":"[(68)Ga]Ga-DOTA-TOC PET\/CT fused to MRI in post-operative evaluation of olfactory groove meningioma: a case on millimetric remnants","volume":"48","author":"Salgues","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib1055","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-015-1838-6","article-title":"Hypofractionated stereotactic radiation therapy in skull base meningiomas","volume":"124","author":"Navarria","year":"2015","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3171\/2014.7.JNS131644","article-title":"Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review","volume":"122","author":"Rogers","year":"2015","journal-title":"J Neurosurg"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib1065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.14338\/IJPT-18-00045.1","article-title":"Clinical outcomes of recurrent intracranial meningiomas treated with proton beam reirradiation","volume":"5","author":"Imber","year":"2019","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.neurol.2023.03.006_bib1070","doi-asserted-by":"crossref","DOI":"10.1159\/000509090","article-title":"Parasellar meningiomas","author":"Graillon","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib1075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.21037\/cco.2016.07.05","article-title":"Proton therapy for tumors of the base of the skull","volume":"5","author":"Noel","year":"2016","journal-title":"Chin Clin Oncol"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib1080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1227\/01.NEU.0000337578.00814.75","article-title":"Radiosurgery with the world's first fully robotized Leksell Gamma Knife PerfeXion in clinical use: a 200-patient prospective, randomized, controlled comparison with the Gamma Knife 4C","volume":"64","author":"Regis","year":"2009","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib1085","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000519280","article-title":"Mask-based versus frame-based gamma knife ICON radiosurgery in brain metastases: a prospective randomized trial","volume":"100","author":"Regis","year":"2022","journal-title":"Stereotact Funct Neurosurg"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1090","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12885-022-09321-w","article-title":"Primary versus postoperative gamma knife radiosurgery for intracranial benign meningiomas: a matched cohort retrospective study","volume":"22","author":"Fu","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib1095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/brainsci11030375","article-title":"(68)Ga-DOTATOC PET\/CT follow-up after single or hypofractionated gamma knife ICON radiosurgery for meningioma patients","volume":"11","author":"Barone","year":"2021","journal-title":"Brain Sci"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2022.08.064","article-title":"Hypofractionated radiosurgery for large or in critical-site intracranial meningioma: results of a phase 2 prospective study","volume":"115","author":"Pinzi","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib1105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/COC.0b013e318271b36a","article-title":"A comparative study of stereotactic radiosurgery, hypofractionated, and fractionated stereotactic radiotherapy in the treatment of skull base meningioma","volume":"37","author":"Han","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.neurol.2023.03.006_bib1110","first-page":"29","article-title":"Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"22","author":"Hartrampf","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.neurol.2023.03.006_bib1115","doi-asserted-by":"crossref","first-page":"102141","DOI":"10.1016\/j.ctrv.2020.102141","article-title":"Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis","volume":"93","author":"Strosberg","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib1120","first-page":"193","article-title":"Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature","volume":"29","author":"Minutoli","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib1125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial","volume":"56","author":"Marincek","year":"2015","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.neurol.2023.03.006_bib1130","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.006_bib1135","first-page":"1538","article-title":"Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake","volume":"18","author":"Seystahl","year":"2016","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.006_bib1140","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","article-title":"90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas","volume":"56","author":"Gerster-Gillieron","year":"2015","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib1145","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/a-1200-0989","article-title":"Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma","volume":"59","author":"Muther","year":"2020","journal-title":"Nuklearmedizin"},{"issue":"8","key":"10.1016\/j.neurol.2023.03.006_bib1150","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.3390\/curroncol29080438","article-title":"Somatostatin receptor theranostics for refractory meningiomas","volume":"29","author":"Salgues","year":"2022","journal-title":"Curr Oncol"},{"issue":"9","key":"10.1016\/j.neurol.2023.03.006_bib1155","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","article-title":"Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma","volume":"36","author":"Bartolomei","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib1160","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/wjnm.wjnm_39_18","volume":"18","author":"Parghane","year":"2019","journal-title":"World J Nucl Med"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib1165","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.120.249607","article-title":"Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: individual patient data meta-analysis","volume":"62","author":"Mirian","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11060-021-03741-7","article-title":"Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort","volume":"153","author":"Le Van","year":"2021","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series","volume":"109","author":"Lou","year":"2012","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","article-title":"Atypical and anaplastic meningiomas treated with bevacizumab","volume":"109","author":"Nayak","year":"2012","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1185","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.006_bib1190","doi-asserted-by":"crossref","first-page":"e0217340","DOI":"10.1371\/journal.pone.0217340","article-title":"Systemic management of malignant meningiomas: a comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib","volume":"14","author":"Cardona","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.006_bib1195","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s00066-013-0505-0","article-title":"Bevacizumab treatment in malignant meningioma with additional radiation necrosis. An MRI diffusion and perfusion case study","volume":"190","author":"Bostrom","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.neurol.2023.03.006_bib1200","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noab019","article-title":"Role of 3-D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study","author":"Graillon","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2023.03.006_bib1205","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.006_bib1210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","article-title":"A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma","volume":"129","author":"Shih","year":"2016","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib1215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw320","article-title":"Durable control of metastatic AKT1-mutant WHO grade 1 meningothelial meningioma by the AKT inhibitor, AZD5363","volume":"109","author":"Weller","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.006_bib1220","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1225","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/neuonc\/noy137","article-title":"Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1230","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","article-title":"A phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas","volume":"117","author":"Raizer","year":"2014","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.006_bib1235","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","volume":"41","author":"Brastianos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurol.2023.03.006_bib1240","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac209.608","article-title":"Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features","author":"Choudhury","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2023.03.006_bib1245","doi-asserted-by":"crossref","first-page":"931371","DOI":"10.3389\/fonc.2022.931371","article-title":"CDK 4\/6 inhibitors for the treatment of meningioma","volume":"12","author":"Young","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/neuonc\/noab118","article-title":"Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results","volume":"24","author":"Bi","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1255","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","article-title":"Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas","volume":"13","author":"Brastianos","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurol.2023.03.006_bib1260","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3389\/fneur.2020.00945","article-title":"Basis for immunotherapy for treatment of meningiomas","volume":"11","author":"Garzon-Muvdi","year":"2020","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib1265","first-page":"364","article-title":"Safe surgery for glioblastoma: recent advances and modern challenges","volume":"9","author":"Gerritsen","year":"2022","journal-title":"Neurooncol Pract"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.006_bib1270","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11060-019-03342-5","article-title":"Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study","volume":"146","author":"Mooney","year":"2020","journal-title":"J Neurooncol"},{"key":"10.1016\/j.neurol.2023.03.006_bib1275","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/B978-0-12-822198-3.00049-5","article-title":"Brachytherapy for meningiomas","volume":"170","author":"Magill","year":"2020","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.006_bib1280","doi-asserted-by":"crossref","first-page":"E910","DOI":"10.1093\/neuros\/nyz115","article-title":"Brachytherapy as an adjuvant for recurrent atypical and malignant meningiomas","volume":"85","author":"Koch","year":"2019","journal-title":"Neurosurgery"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723008810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723008810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:47:53Z","timestamp":1758520073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378723008810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":128,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0035378723008810"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2023.03.006","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative treatments for meningiomas","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2023.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}